Chemokine receptors: Key for molecular imaging of inflammation in atherosclerosis.
作者信息
Liu Yongjian, Woodard Pamela K
机构信息
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
出版信息
J Nucl Cardiol. 2019 Aug;26(4):1179-1181. doi: 10.1007/s12350-018-1248-1. Epub 2018 Mar 7.
Abstract
摘要
相似文献
1
Chemokine receptors: Key for molecular imaging of inflammation in atherosclerosis.
J Nucl Cardiol. 2019 Aug;26(4):1179-1181. doi: 10.1007/s12350-018-1248-1. Epub 2018 Mar 7.
2
Development of an inflammation imaging tracer, In-DOTA-DAPTA, targeting chemokine receptor CCR5 and preliminary evaluation in an ApoE atherosclerosis mouse model.
J Nucl Cardiol. 2019 Aug;26(4):1169-1178. doi: 10.1007/s12350-018-1203-1. Epub 2018 Feb 7.
3
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice.
Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):373-9. doi: 10.1161/01.ATV.0000253886.44609.ae. Epub 2006 Nov 30.
4
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice.
Circ Res. 2004 Feb 6;94(2):253-61. doi: 10.1161/01.RES.0000109793.17591.4E. Epub 2003 Dec 1.
5
Cyanidin-3--β-Glucoside Attenuates Platelet Chemokines and Their Receptors in Atherosclerotic Inflammation of ApoE Mice.
J Agric Food Chem. 2022 Jul 13;70(27):8254-8263. doi: 10.1021/acs.jafc.2c01844. Epub 2022 Jun 27.
6
C-C chemokine receptor type 5 deficiency exacerbates alcoholic fatty liver disease through pro-inflammatory cytokines and chemokines-induced hepatic inflammation.
J Gastroenterol Hepatol. 2017 Jun;32(6):1258-1264. doi: 10.1111/jgh.13657.
7
Chemoattraction of T cells expressing CCR5, CXCR3 and CX3CR1 by proximal tubular epithelial cell chemokines.
Nephrol Dial Transplant. 2002 May;17(5):734-44. doi: 10.1093/ndt/17.5.734.
8
The contribution of chemokines and chemokine receptors to the rejection of fetal proislet allografts.
Cell Transplant. 2004;13(5):503-14. doi: 10.3727/000000004783983611.
9
Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5.
Biochemistry. 1997 Aug 12;36(32):9642-8. doi: 10.1021/bi970593z.
10
Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice.
Circulation. 2008 Apr 1;117(13):1649-57. doi: 10.1161/CIRCULATIONAHA.107.745091. Epub 2008 Mar 17.
引用本文的文献
1
Positron Emission Tomography Imaging of the Adaptive Immune System in Cardiovascular Diseases.
Chem Biomed Imaging. 2025 Mar 19;3(4):209-224. doi: 10.1021/cbmi.4c00117. eCollection 2025 Apr 28.
2
Molecular imaging research in atherosclerosis: A 23-year scientometric and visual analysis.
Front Bioeng Biotechnol. 2023 Apr 13;11:1152067. doi: 10.3389/fbioe.2023.1152067. eCollection 2023.
3
Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential.
J Clin Med. 2021 Aug 26;10(17):3825. doi: 10.3390/jcm10173825.
4
PET Imaging Radiotracers of Chemokine Receptors.
Molecules. 2021 Aug 26;26(17):5174. doi: 10.3390/molecules26175174.
5
CC Chemokine Receptor 5 Targeted Nanoparticles Imaging the Progression and Regression of Atherosclerosis Using Positron Emission Tomography/Computed Tomography.
Mol Pharm. 2021 Mar 1;18(3):1386-1396. doi: 10.1021/acs.molpharmaceut.0c01183. Epub 2021 Feb 16.
本文引用的文献
1
Development of an inflammation imaging tracer, In-DOTA-DAPTA, targeting chemokine receptor CCR5 and preliminary evaluation in an ApoE atherosclerosis mouse model.
J Nucl Cardiol. 2019 Aug;26(4):1169-1178. doi: 10.1007/s12350-018-1203-1. Epub 2018 Feb 7.
2
Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden.
J Nucl Med. 2018 Feb;59(2):266-272. doi: 10.2967/jnumed.117.196485. Epub 2017 Aug 3.
3
Thermoneutrality but Not UCP1 Deficiency Suppresses Monocyte Mobilization Into Blood.
Circ Res. 2017 Sep 1;121(6):662-676. doi: 10.1161/CIRCRESAHA.117.311519. Epub 2017 Jul 10.
4
Design and Modular Construction of a Polymeric Nanoparticle for Targeted Atherosclerosis Positron Emission Tomography Imaging: A Story of 25% (64)Cu-CANF-Comb.
Pharm Res. 2016 Oct;33(10):2400-10. doi: 10.1007/s11095-016-1963-8. Epub 2016 Jun 10.
5
Imaging Atherosclerosis.
Circ Res. 2016 Feb 19;118(4):750-69. doi: 10.1161/CIRCRESAHA.115.306247.
6
Atherosclerosis: Successes, Surprises, and Future Challenges.
Circ Res. 2016 Feb 19;118(4):531-4. doi: 10.1161/CIRCRESAHA.116.308334.
7
PET/CT Imaging of Chemokine Receptors in Inflammatory Atherosclerosis Using Targeted Nanoparticles.
J Nucl Med. 2016 Jul;57(7):1124-9. doi: 10.2967/jnumed.115.166751. Epub 2016 Jan 21.
8
Recent Advances of Radionuclide-Based Molecular Imaging of Atherosclerosis.
Curr Pharm Des. 2015;21(36):5267-76. doi: 10.2174/1381612821666150915104529.
9
Chemokines and their receptors in Atherosclerosis.
J Mol Med (Berl). 2015 Sep;93(9):963-71. doi: 10.1007/s00109-015-1317-8. Epub 2015 Jul 15.
10
PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle.
J Nucl Med. 2014 Apr;55(4):629-34. doi: 10.2967/jnumed.113.132001. Epub 2014 Mar 3.
Zotero 插件